AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation GlobeNewswire - Mon Nov 23, 7:30AM CST CMTX - Mon Nov 23, 7:30AM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the...
ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire - Mon Nov 2, 7:30AM CST CMTX - Mon Nov 2, 7:30AM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported financial...
ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19 GlobeNewswire - Wed Oct 7, 7:30AM CDT CMTX - Wed Oct 7, 7:30AM CDT
-- Initiation of Phase 2b clinical trial anticipated in Q4 2020
ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality GlobeNewswire - Mon Oct 5, 3:30PM CDT CMTX - Mon Oct 5, 3:30PM CDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced the promotion...
ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19 GlobeNewswire - Mon Sep 21, 7:00AM CDT CMTX - Mon Sep 21, 7:00AM CDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced it has...
ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201 as a Potential Treatment for Severe COVID-19 ACCESSWIRE - Wed Aug 12, 7:01AM CDT CMTX - Wed Aug 12, 7:01AM CDT
ARCA anticipates filing an IND for AB201 for COVID-19 in September 2020 and initiating Phase 2B clinical testing as early as Q4 2020
Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire - Wed Aug 5, 3:15PM CDT CMTX - Wed Aug 5, 3:15PM CDT
-- ARCA anticipates filing an IND for AB201 in Q3 2020 and initiating Phase 2 clinical testing in Q4 2020
ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering GlobeNewswire - Wed Jun 3, 8:56AM CDT CMTX - Wed Jun 3, 8:56AM CDT
ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced...
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More Zacks Equity Research - Zacks Investment Research - Wed Jun 3, 8:56AM CDT Zacks Equity Research - ZACKS - Wed Jun 3, 8:56AM CDT
The biotech sector remains in focus with updates on coronavirus treatments and presentations at ASCO.
ARCA Biopharma Announces $9.4 Million Registered Direct Offering GlobeNewswire - Mon Jun 1, 7:22AM CDT CMTX - Mon Jun 1, 7:22AM CDT
ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced...
Company News for May 29, 2020 Zacks Equity Research - Zacks Investment Research - Fri May 29, 8:59AM CDT Zacks Equity Research - ZACKS - Fri May 29, 8:59AM CDT
Companies In The News Are: ABIO, ARPO, LL, DLTR
ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy GlobeNewswire - Thu May 28, 7:00AM CDT CMTX - Thu May 28, 7:00AM CDT
-- AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients with COVID-19
Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions GlobeNewswire - Thu May 7, 7:30AM CDT CMTX - Thu May 7, 7:30AM CDT
New data provide additional evidence of efficacy for Gencaro compared to active control in a pharmacogenetically-defined HF population at risk for AF recurrence
ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update GlobeNewswire - Wed May 6, 3:30PM CDT CMTX - Wed May 6, 3:30PM CDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported financial...
ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update GlobeNewswire - Tue Feb 18, 3:30PM CST CMTX - Tue Feb 18, 3:30PM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial...
ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire - Wed Nov 6, 3:10PM CST CMTX - Wed Nov 6, 3:10PM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial...
ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium GlobeNewswire - Thu Sep 12, 7:30AM CDT CMTX - Thu Sep 12, 7:30AM CDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that Dr....
Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting GlobeNewswire - Wed Sep 11, 7:30AM CDT CMTX - Wed Sep 11, 7:30AM CDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that Gencaro...
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abiomed, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire - Wed Aug 21, 8:49AM CDT CMTX - Wed Aug 21, 8:49AM CDT
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abiomed, Inc. ("Abiomed" or "the Company") (NASDAQ: ABMD) for violations of §§10(b)...
ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire - Thu Aug 1, 3:30PM CDT CMTX - Thu Aug 1, 3:30PM CDT
-- FDA SPA Agreement for Phase 3 atrial fibrillation trial (PRECISION-AF) amended to expand patient population to include heart failure patients with preserved ejection fraction (HFpEF)
InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.